FM is also a diagnosis of exclusion
Last reviewed: June 11, 2026 Last updated: June 11, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Injection Sites: Use fatty areas like the abdomen (away from navel), thighs, hips, or upper arms
Fernandez-Mendivil C, Luengo E, Trigo-Alonso P, Garcia-Magro N, Negredo P, Lopez MG
enzyme deficiencies of alpha-aminoadipic semialdehyde dehydrogenase and the saccharopine dehydrogenases have been associated with hyperlysinemia